Skip to main content
SpringerLink
Log in

Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?

  • Letter to the Editor
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 26 February 2018

The Original Article was published on 27 October 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Barrio P, Ortega L, Guardia J, Roncero C, Yuguero L, Gual A. Who receives nalmefene and how does it work in the real world? A single-arm, Phase IV study of nalmefene in alcohol dependent outpatients: baseline and 1-month results. Clin Drug Investig. 2017. https://doi.org/10.1007/s40261-017-0590-4.

    Google Scholar 

  2. National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. 2011. https://www.nice.org.uk/guidance/cg115/chapter/1-Guidance.

  3. Braillon A. Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency. BMJ. 2014;348:g2017.

    Article  PubMed  Google Scholar 

  4. Spence D. Bad medicine: nalmefene in alcohol misuse. BMJ. 2014;348:g1531.

    Article  PubMed  Google Scholar 

  5. Stevenson M, Pandor A, Stevens JW, Rawdin A, Rice P, Thompson J, Morgan MY. Nalmefene for reducing alcohol consumption in people with alcohol dependence: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2015;33:833–47.

    Article  PubMed  Google Scholar 

  6. Braillon A, Granger B. Nalmefene and alcohol dependence: a new approach or the same old unacceptable marketing? Subst Abuse Rehabil. 2015;6:75–80.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F. Risks and benefits of nalmefene in the treatment of adult alcohol aependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 2015;12:e1001924.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Naudet F, Fitzgerald N, Braillon A. Nalmefene for alcohol dependence: a NICE decision? Lancet Psychiatry. 2016;3:1104–5.

    Article  PubMed  Google Scholar 

  9. Fitzgerald N, Angus K, Elders A, de Andrade M, Raistrick D, Heather N, McCambridge J. Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. Addiction. 2016;111:1477–87.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Palpacuer C, Duprez R, Huneau A, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2017. https://doi.org/10.1111/add.13974.

    PubMed  Google Scholar 

  11. Baumann S, Toft U, Aadahl M, Jørgensen T, Pisinger C. The long-term effect of a population-based life-style intervention on smoking and alcohol consumption. The Inter99 Study—a randomized controlled trial. Addiction. 2015;110:1853–60.

    Article  PubMed  Google Scholar 

  12. Rehm J, Shield K: Alcohol consumption. In Stewart BW, Wild CB, editors. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer; 2014.

  13. Pendery ML, Maltzman IM, West LJ. Controlled drinking by alcoholics? New findings and a reevaluation of a major affirmative study. Science. 1982;217:169–75.

    Article  CAS  PubMed  Google Scholar 

  14. Johansen KGV, Tarp S, Astrup A, Lund H, Pagsberg AK. Christensen R Harms associated with taking nalmefene for substance use and impulse control disorders: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2017;12:e0183821.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol. 2004;72:1144–56.

    Article  PubMed  Google Scholar 

  16. Psychotherapy: Quebec to invest $35 million in mental health. Available from: http://montrealgazette.com/news/local-news/psychotherapy-quebec-to-invest-35-million-in-mental-health. Accessed 30 Jan 2018.

Download references

Funding

Funding

No source of funding was used to prepare this letter.

Author information

Authors and Affiliations

  1. Alcohol Treatment Unit, University Hospital, 80000, Amiens, France

    Alain Braillon & Francoise Taiebi

  2. Faculty of Psychology, University of Picardie Jules Verne, 80000, Amiens, France

    Francoise Taiebi & Amal Bernoussi

Authors
  1. Alain Braillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francoise Taiebi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amal Bernoussi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alain Braillon.

Ethics declarations

Conflict of interest

All authors have no conflicts of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Braillon, A., Taiebi, F. & Bernoussi, A. Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?. Clin Drug Investig 38, 385–386 (2018). https://doi.org/10.1007/s40261-018-0628-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-018-0628-2

Search

Navigation